摩熵化学
数据库官网
小程序
打开微信扫一扫
首页 分子通 化学资讯 化学百科 反应查询 关于我们
请输入关键词

溴甲酰溴 | 593-95-3

中文名称
溴甲酰溴
中文别名
——
英文名称
carbonyl dibromide
英文别名
——
溴甲酰溴化学式
CAS
593-95-3
化学式
CBr2O
mdl
——
分子量
187.82
InChiKey
MOIPGXQKZSZOQX-UHFFFAOYSA-N
BEILSTEIN
——
EINECS
——
  • 物化性质
  • 计算性质
  • ADMET
  • 安全信息
  • SDS
  • 制备方法与用途
  • 上下游信息
  • 反应信息
  • 文献信息
  • 表征谱图
  • 同类化合物
  • 相关功能分类
  • 相关结构分类

物化性质

  • 熔点:
    65℃ [COT88]
  • 沸点:
    64.5°C
  • 密度:
    2.500
  • 溶解度:
    与H2O反应

计算性质

  • 辛醇/水分配系数(LogP):
    2
  • 重原子数:
    4
  • 可旋转键数:
    0
  • 环数:
    0.0
  • sp3杂化的碳原子比例:
    0.0
  • 拓扑面积:
    17.1
  • 氢给体数:
    0
  • 氢受体数:
    1

SDS

SDS:a1f6257ff402a7f4c75c3f2ad81e665e
查看

反应信息

点击查看最新优质反应信息

文献信息

  • Caspase inhibitors and uses thereof
    申请人:——
    公开号:US20040072850A1
    公开(公告)日:2004-04-15
    The present invention relates to compounds of formula I: 1 useful as inhibitors of caspases. The present invention also provides pharmaceutically acceptable compositions comprising said compounds, processes for preparing the compounds, and methods of using the compounds and compositions in the treatment of various diseases, conditions, or disorders.
    本发明涉及公式I的化合物:1,用作caspases的抑制剂。本发明还提供了包含所述化合物的药学上可接受的组合物,制备所述化合物的方法,以及使用所述化合物和组合物治疗各种疾病、状况或障碍的方法。
  • Azole derivatives and fused bicyclic azole derivatives as therapeutic agents
    申请人:——
    公开号:US20040082542A1
    公开(公告)日:2004-04-29
    This invention provides certain compounds, methods of their preparation, pharmaceutical compositions comprising the compounds, and their use in treating human or animal disorders. The compounds of the invention are useful as modulators of the interaction between the receptor for advanced glycated end products (RAGE) and its ligands, such as advanced glycated end products (AGEs), S100/calgranulin/EN-RAGE, &bgr;-amyloid and amphoterin, and for the management, treatment, control, or as an adjunct treatment for diseases in humans caused by RAGE. Such diseases or disease states include acute and chronic inflammation, the development of diabetic late complications such as increased vascular permeability, nephropathy, atherosclerosis, and retinopathy, the development of Alzheimer's disease, erectile dysfunction, and tumor invasion and metastasis.
    本发明提供了某些化合物、它们的制备方法、包含这些化合物的药物组合物以及它们在治疗人类或动物疾病中的应用。本发明的化合物可用作高级糖基化终产物受体(RAGE)及其配体(如高级糖基化终产物(AGEs)、S100/calgranulin/EN-RAGE、β-淀粉样蛋白和amphoterin)之间相互作用的调节剂,并用于治疗由RAGE引起的人类疾病的管理、治疗、控制或作为辅助治疗。这些疾病或疾病状态包括急性和慢性炎症、糖尿病晚期并发症的发展(如增加的血管通透性、肾病、动脉粥样硬化和视网膜病变)、阿尔茨海默病的发展、勃起功能障碍以及肿瘤侵袭和转移。
  • Gastrin and cholecystokinin receptor ligands(II)
    申请人:——
    公开号:US20030199565A1
    公开(公告)日:2003-10-23
    Substituted imidazoles (1) are useful as angiotensin II blockers. These compounds have activity in treating hypertension and congestive heart failure. Pharmaceutical compositions containing the novel imidazoles and pharmaceutical methods using them, alone and in conjunction with other drugs, especially diuretics and non-steroidal antiinflammatory drugs (NSAID's) are also described.
    取代咪唑(1)可用作血管紧张素II阻滞剂。这些化合物在治疗高血压和充血性心力衰竭中具有活性。还描述了含有新型咪唑的制药组合物以及使用它们的制药方法,单独或与其他药物一起使用,尤其是利尿剂和非甾体抗炎药(NSAID's)。
  • Fused pyrrole compounds, pharmaceutical agents containing the same, and the use thereof
    申请人:——
    公开号:US20040122002A1
    公开(公告)日:2004-06-24
    The present invention relates to fused pyrrole compounds of the formula 1. 1 in which at least one of the radicals R1, R2, R3 is 4-sulphur-substituted phenyl. These compounds are in particular pyrrolizines, indolizines and heteroanalogues having selective inhibitory action on isoenzyme-2 of prostaglandin H synthase (COX-2). The invention also relates to pharmaceutical compositions which contain these compounds; and the use of these compounds for the treatment of disorders of the rheumatic type.
    本发明涉及式1.1的融合吡咯化合物,其中至少一个基团R1、R2、R3是4-代取代苯基。这些化合物特别是吡咯啉、吲哚啉和杂环类似物,具有对前列腺素H合成酶同工酶2的选择性抑制作用。本发明还涉及含有这些化合物的药物组合物;以及使用这些化合物治疗风湿性疾病的方法。
  • Low-temperature, aqueous conversion of 4-picoline derivative to
    申请人:Sterling Drug Inc.
    公开号:US04310670A1
    公开(公告)日:1982-01-12
    The process which comprises reacting 4-picoline below about 30.degree. C. with at least three mole equivalents of an inorganic acid halide, preferably phosphorus oxychloride, per mole of 4-picoline and excess dimethylformamide, reacting in solution the unisolated resulting N-[3-dimethylamino-2-(4-pyridinyl)-2-propenylidene]-N-methylmethaniminium salt (after adding the reaction mixture to cold water, adjusting the pH to about 8.0 and filtering off the precipitated inorganic cationic salts) with excess .alpha.-cyanoacetamide and at least three mole equivalents of base, and then isolating 5-cyano-[3,4'-bipyridin]-6(1H)-one in free base form (after neutralization) or in the form of its inorganic cationic salt. Said 5-cyano-[3,4'-bipyridin]-6(1H)-one is an intermediate for preparing the cardiotonic amrinone.
    该过程包括在大约30℃以下反应4-哌啶与至少三摩尔当量的无机酸卤化物,优选磷酸化物,每摩尔4-哌啶和过量二甲基甲酰胺反应溶液中未分离的生成的N-[3-二甲基基-2-(4-吡啶基)-2-丙烯亚胺基]-N-甲基甲酰胺盐(将反应混合物加入冷,将pH调节到约8.0并过滤沉淀的无机阳离子盐),与过量的α-乙酰胺和至少三摩尔当量的碱反应,并随后在中和后以自由碱或其无机阳离子盐的形式分离5-基-[3,4'-联吡啶]-6(1H)-酮。所述5-基-[3,4'-联吡啶]-6(1H)-酮是制备心力衰竭药物阿米洛酮的中间体。
查看更多